|
US3254124A
(en)
|
1962-06-29 |
1966-05-31 |
Parke Davis & Co |
Aminoketones and methods for their production
|
|
CH535201A
(de)
|
1969-12-19 |
1973-03-31 |
Bristol Myers Co |
Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
|
|
US4670459A
(en)
|
1984-10-03 |
1987-06-02 |
Merrell Dow Pharmaceuticals Inc. |
Method of alleviating withdrawal symptoms
|
|
US5679714A
(en)
|
1995-06-07 |
1997-10-21 |
Weg; Stuart L. |
Administration of ketamine for detoxification and treatment of tobacco addiction
|
|
US5543434A
(en)
|
1994-02-25 |
1996-08-06 |
Weg; Stuart L. |
Nasal administration of ketamine to manage pain
|
|
DE19619665C2
(de)
|
1996-05-15 |
2001-03-08 |
Goedecke Ag |
Racemattrennung von Ketamin
|
|
US6248789B1
(en)
|
1996-08-29 |
2001-06-19 |
Stuart L. Weg |
Administration of ketamine to manage pain and to reduce drug dependency
|
|
US7001609B1
(en)
|
1998-10-02 |
2006-02-21 |
Regents Of The University Of Minnesota |
Mucosal originated drug delivery systems and animal applications
|
|
US6382204B1
(en)
|
1999-10-14 |
2002-05-07 |
Becton Dickinson And Company |
Drug delivery system including holder and drug container
|
|
US6962151B1
(en)
|
1999-11-05 |
2005-11-08 |
Pari GmbH Spezialisten für effektive Inhalation |
Inhalation nebulizer
|
|
SI1257648T2
(sl)
|
2000-02-23 |
2016-11-30 |
Amgen Inc. |
Antagonistični selektivni vezavni agensi za osteoprotegerin vezavni protein
|
|
BRPI0002693B8
(pt)
|
2000-06-19 |
2021-05-25 |
Cristalia Produtos Quim Farmaceuticos Ltda |
processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis
|
|
US7090830B2
(en)
|
2001-05-24 |
2006-08-15 |
Alexza Pharmaceuticals, Inc. |
Drug condensation aerosols and kits
|
|
CA2529857A1
(en)
|
2002-07-30 |
2004-02-05 |
Peter Migaly |
Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
|
|
US7273889B2
(en)
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
|
JP2006510618A
(ja)
|
2002-11-18 |
2006-03-30 |
ヤウポン セラピューティクス，インコーポレーテッド |
ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用
|
|
US7713440B2
(en)
|
2003-10-08 |
2010-05-11 |
Lyotropic Therapeutics, Inc. |
Stabilized uncoated particles of reversed liquid crystalline phase materials
|
|
US7928132B2
(en)
|
2004-08-06 |
2011-04-19 |
Ohio University |
Methods for the amelioration of episodes of acute or chronic ulcerative colitis
|
|
KR101271263B1
(ko)
|
2005-09-28 |
2013-06-07 |
아우리스 메디칼 아게 |
내이 장애 치료용 약학 조성물
|
|
AU2007229866A1
(en)
|
2006-03-22 |
2007-10-04 |
Mount Sinai School Of Medicine |
Intranasal administration of ketamine to treat depression
|
|
BRPI0809843A2
(pt)
|
2007-04-26 |
2014-09-23 |
Auspex Pharmaceuticals Inc |
"composto, composição farmacêutica e uso de um composto"
|
|
US20120225949A1
(en)
*
|
2009-08-14 |
2012-09-06 |
Demitri Papalos |
Compositions and methods for treating bipolar disorder
|
|
US20110038807A1
(en)
*
|
2009-08-14 |
2011-02-17 |
Demitri Papolos |
Compositions and methods for treating bipolar disorder
|
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
|
WO2013138322A1
(en)
|
2012-03-12 |
2013-09-19 |
Janssen Pharmaceutica Nv |
Esketamine for the treatment of treatment-refractory or treatment-resistant depression
|
|
EP2830604A4
(en)
|
2012-03-30 |
2015-08-19 |
Gen Hospital Corp |
COMPOSITIONS WITH SCOPOLAMINE AND KETAMINE FOR THE TREATMENT OF DEPRESSIONS
|
|
KR20150096370A
(ko)
|
2012-08-23 |
2015-08-24 |
스튜어트 엘. 웨그 |
항불안제 조성물, 제형 및 사용방법
|
|
US20140274981A1
(en)
|
2013-03-15 |
2014-09-18 |
Janssen Pharmaceutica Nv |
Pharmaceutical composition of s-ketamine hydrochloride
|
|
DK2968221T3
(da)
|
2013-03-15 |
2019-08-05 |
Janssen Pharmaceutica Nv |
Farmaceutisk sammensætning af s-ketaminhydrochlorid
|
|
DK2983787T3
(da)
|
2013-04-12 |
2020-01-06 |
Icahn School Med Mount Sinai |
Fremgangsmåde til behandling af posttraumatisk stresssygdom
|
|
HUE056378T2
(hu)
*
|
2013-09-13 |
2022-02-28 |
Univ Chiba Nat Univ Corp |
R-Ketamin és sójának alkalmazása gyógyszerekként
|
|
WO2015051259A1
(en)
|
2013-10-04 |
2015-04-09 |
Impax Laboratories, Inc. |
Pharmaceutical compositions and methods of use
|
|
EP3094312B1
(en)
|
2014-01-14 |
2019-03-13 |
Children's Hospital Medical Center |
Compositions comprising ketamine for treating an autism spectrum disorder
|
|
JP6462002B2
(ja)
|
2014-04-29 |
2019-01-30 |
ザ カトリック ユニバーシティ オブ コリア インダストリー−アカデミック コーオペレイション ファウンデーション |
免疫疾患治療効果を有する新規化合物およびその使用
|
|
KR20170040800A
(ko)
|
2014-08-13 |
2017-04-13 |
얀센 파마슈티카 엔.브이. |
우울증 치료 방법
|
|
AU2015318123A1
(en)
|
2014-09-15 |
2017-03-30 |
Janssen Pharmaceutica Nv |
Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
|
|
DK3215147T3
(da)
|
2014-11-04 |
2024-04-02 |
Acadia Pharm Inc |
Neurodæmpende norketamin-forbindelser og fremgangsmåder
|
|
EP3085366A1
(en)
|
2015-04-22 |
2016-10-26 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
|
|
US20160332962A1
(en)
|
2015-05-13 |
2016-11-17 |
Janssen Pharmaceutica Nv |
(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
|
|
US11426366B2
(en)
|
2015-05-15 |
2022-08-30 |
Arizona Board Of Regents On Behalf Of The Universsity Of Arizona |
Compositions and methods for treating motor disorders
|
|
US20200297734A1
(en)
|
2015-06-19 |
2020-09-24 |
Melt Pharmaceuticals, Inc. |
Pharmaceutical compositions and methods for anesthesiological applications
|
|
US9918993B2
(en)
|
2015-06-19 |
2018-03-20 |
Imprimis Pharmaceuticals, Inc. |
Pharmaceutical compositions for anesthesiological applications
|
|
CN107847469A
(zh)
|
2015-06-27 |
2018-03-27 |
美国神农制药责任有限公司 |
氯胺酮透皮递送系统
|
|
US11110070B2
(en)
|
2015-11-17 |
2021-09-07 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
|
|
CA3019012A1
(en)
|
2016-03-25 |
2017-09-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
|
|
EP3442940A1
(en)
|
2016-04-11 |
2019-02-20 |
Clexio Biosciences Ltd. |
Deuterated ketamine derivatives
|
|
US20200261442A1
(en)
|
2016-08-26 |
2020-08-20 |
Sreenivasarao Vepachedu |
Targeted drug rescue with novel compositions, combinations, and methods thereof
|
|
US11103499B2
(en)
|
2016-08-26 |
2021-08-31 |
EXCIVA (UG) (haftungsbeschränkt) |
Compositions and methods thereof
|
|
WO2018075481A1
(en)
|
2016-10-17 |
2018-04-26 |
Yale University |
Compounds, compositions and methods for treating or preventing depression and other diseases
|
|
AU2017351437B2
(en)
|
2016-10-27 |
2022-01-27 |
National University Corporation Chiba University |
Application of (S)-norketamine and salt thereof as pharmaceutical
|
|
US20180177743A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain using racemic mixture of s-ketamine and r-ketamine
|
|
EP3562529A4
(en)
|
2016-12-27 |
2021-03-03 |
Action Medical Technologies, LLC |
APPARATUS AND METHOD FOR INJECTING MEDICINES
|
|
AU2018215056A1
(en)
|
2017-01-31 |
2019-08-08 |
Charles E. Inturrisi |
D-methadone and its derivatives for use in the treatment of disorders of the nervous system
|
|
US11478467B2
(en)
|
2017-05-04 |
2022-10-25 |
Sreenivasarao Vepachedu |
Targeted drug rescue with novel compositions, combinations, and methods thereof
|
|
CA3064846A1
(en)
|
2017-05-25 |
2018-11-29 |
Glytech, Llc |
Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders
|
|
WO2018234568A2
(en)
|
2017-06-23 |
2018-12-27 |
Develco Pharma Schweiz Ag |
HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
|
|
US20200405663A1
(en)
|
2017-09-27 |
2020-12-31 |
National University Corporation Chiba University |
R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition functional disorder
|
|
US10441544B2
(en)
|
2017-10-10 |
2019-10-15 |
Douglas Pharmaceuticals, Ltd. |
Extended release pharmaceutical formulation
|
|
US10869838B2
(en)
|
2017-10-10 |
2020-12-22 |
Douglas Pharmaceuticals, Ltd. |
Extended release pharmaceutical formulation
|
|
WO2019094757A1
(en)
|
2017-11-09 |
2019-05-16 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders in females
|
|
CN107823195A
(zh)
|
2017-11-24 |
2018-03-23 |
无锡市精神卫生中心 |
R‑氯胺酮在抑郁症急性期治疗中的应用
|
|
EP3505509A1
(en)
|
2017-12-29 |
2019-07-03 |
Université de Liège |
Methods for the preparation of arylcycloalkylamine derivatives
|
|
PL3737665T3
(pl)
|
2018-01-10 |
2026-04-20 |
XWPharma Ltd. |
Proleki ketaminy, ich kompozycje i zastosowania
|
|
US11980595B2
(en)
|
2018-02-15 |
2024-05-14 |
National University Corporation Chiba University |
Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
|
|
WO2019169165A1
(en)
|
2018-02-28 |
2019-09-06 |
Novocine Therapeutics, Llc |
Ketamine and ketamine-related compounds for the treatment of neurological disorders
|
|
EP3761970A4
(en)
|
2018-03-26 |
2022-06-08 |
Cellix Bio Private Limited |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
|
|
WO2019213551A1
(en)
|
2018-05-04 |
2019-11-07 |
Perception Neuroscience, Inc. |
Methods of treating substance abuse
|
|
GB201809976D0
(en)
|
2018-06-18 |
2018-08-01 |
Neurocentrx Pharma Ltd |
Novel formulations
|
|
BR112020023882A2
(pt)
|
2018-06-27 |
2021-02-09 |
Clexio Biosciences Ltd. |
método para tratar transtorno depressivo maior
|
|
US12090145B2
(en)
|
2018-08-20 |
2024-09-17 |
Yale University |
Combination therapy for treating or preventing depression or other mood diseases
|
|
CN112702995A
(zh)
|
2018-10-05 |
2021-04-23 |
克雷西奥生物科技有限公司 |
治疗重度抑郁症的艾氯胺酮的治疗方案
|
|
EP3863617A1
(en)
|
2018-10-11 |
2021-08-18 |
Clexio Biosciences Ltd. |
Esketamine for use in treating major depressive disorder
|
|
WO2020138491A1
(ja)
|
2018-12-27 |
2020-07-02 |
国立大学法人千葉大学 |
神経発達障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体
|
|
PL3908570T3
(pl)
|
2019-01-11 |
2024-07-01 |
Alar Pharmaceuticals Inc. |
Embonian ketaminy i jego zastosowanie
|
|
WO2020198039A1
(en)
|
2019-03-23 |
2020-10-01 |
Sermone Sandra |
Ketamine for treatment of sensory processing deficits
|
|
EP3956300A1
(en)
|
2019-04-16 |
2022-02-23 |
Janssen Pharmaceutica NV |
Synthetic methods of preparing esketamine
|
|
EP3968979A4
(en)
|
2019-05-15 |
2023-03-01 |
Bexson Biomedical, Inc. |
KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
|
|
CA3133012A1
(en)
|
2019-08-05 |
2021-02-11 |
The Ketamine Research Foundation |
Ketamine for the treatment of postpartum symptoms and disorders
|
|
US11007200B2
(en)
|
2019-08-21 |
2021-05-18 |
MediSynergics, LLC |
Cycloalkyl-diamines for the treatment of pain
|
|
PH12022550775A1
(en)
|
2019-12-20 |
2023-08-23 |
Alar Pharmaceuticals Inc |
Long-acting injectable formulations of ketamine pamoate salts
|
|
CN119241381A
(zh)
|
2019-12-26 |
2025-01-03 |
吉尔伽美什制药公司 |
芳基环己基胺衍生物及其在精神障碍的治疗中的用途
|
|
EP4084786A1
(en)
|
2019-12-30 |
2022-11-09 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating major depressive disorder
|
|
JP2023507926A
(ja)
|
2019-12-30 |
2023-02-28 |
クレキシオ バイオサイエンシーズ エルティーディー． |
神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
|
|
JP2023511370A
(ja)
|
2020-01-22 |
2023-03-17 |
シーロス セラピューティクス， インコーポレイテッド |
Ｎｍｄａ拮抗薬の副作用の低減
|
|
AU2021242363A1
(en)
|
2020-03-27 |
2022-11-03 |
Homeostasis Therapeutics, Limited |
Method of treatment for anorexia nervosa, bulimia and related clinical syndromes
|
|
JP7821116B2
(ja)
|
2020-04-07 |
2026-02-26 |
ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク |
ストレス誘導性恐怖、うつ様行動および不安様行動の予防のための組成物および方法
|
|
US12128012B2
(en)
|
2020-05-15 |
2024-10-29 |
University Of Kansas |
Ketamine treatment for amyotrophic lateral sclerosis
|
|
WO2021252971A2
(en)
|
2020-06-12 |
2021-12-16 |
Bexson Biomedical, Inc. |
Systems and devices for controlled drug delivery
|
|
US20230265046A1
(en)
|
2020-06-17 |
2023-08-24 |
Spirify Pharma Inc. |
Hydroxynorketamine analogues, compositions comprising same and methods of use thereof
|
|
IL312041A
(en)
|
2021-10-12 |
2024-06-01 |
Perception Neuroscience Inc |
R-ketamine salts and methods of using them
|
|
EP4493155A1
(en)
|
2022-03-14 |
2025-01-22 |
Perception Neuroscience, Inc. |
Pharmaceutical formulations of r-ketamine
|
|
US20250281426A1
(en)
|
2022-04-26 |
2025-09-11 |
Yichang Humanwell Pharmaceutical Co., Ltd. |
R-ketamine liquid preparation and use thereof
|
|
EP4642445A2
(en)
|
2022-12-28 |
2025-11-05 |
Perception Neuroscience, Inc. |
Methods of administering r-ketamine
|